MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "mixed" rating to a "sell" rating.